Wroclaw-based Biotts is creating a new category of drugs. What is their unique transdermal system?

Biotts has just completed the next stage of preclinical studies for one of the drug candidates they have developed by combining a carrier with an anti-diabetic substance. In 2023, the company is starting the first phase of human clinical trials.

– We have obtained positive results in large and small rodents, which has allowed us to proceed to the next phase, which is studies in larger animals. Studies on pigs are in progress, we are in constant contact with the centre and there are no objections to our transdermal systems, we expect the results at the end of September – Hanna Dopierała-Bartczak, Biotts laboratory manager.

Hanna Dopierała-Bartczak adds that last year the research and development process for dapagliflozin (used in the treatment of type 2 diabetes) was completed.

– We are now preparing methods and validations, thanks to which we will conduct stability studies and then submit full documentation to the Office for Registration of Medicines in order to enter the first phase of clinical trials. We are currently preparing to scale up our technology from the laboratory to production, which is why, through a public tender process, we have selected a company that will manufacture GMP-quality patches for us for clinical trials – emphasises Hanna Dopierała-Bartczak.

Biotts – new drugs administered through the skin instead of injections, tablets and exhausting therapies

The solutions of the Wroclaw-based company make it possible to transport drugs through the skin – until now it has been impossible to administer most therapeutic substances in this way. For patients this could mean the end of injections and tablets.

– Imagine drugs administered for cancer in the form of an ointment or a matrix patch – we act only on locally changed tissues, delivering active substances directly to the place where our body is ill. Patient comfort and the effectiveness of the therapy are very important to us. In this context, the effectiveness of our carrier is important, regardless of whether it is in the form of a patch, ointment or gel, and thanks to the technology we have developed, we carry really large molecules through the skin. This is a breakthrough discovery. Targeted therapy will make it possible to relieve the entire body, and this could mean an end to exhausting therapies – Dr Jan Meler, co-founder of Biotts.

Biotts – a breakthrough discovery from Wroclaw. New drugs for cancer, diabetes and COVID-19

Biotts – a biotech company from Wroclaw, was founded in 2018 on the initiative of two inventors – Dr. Paweł Biernat and Dr. Jan Meler – and an entrepreneur – Konrad Krajewski.

– I have always wondered how to treat the disease-affected tissues, so that the whole organism and healthy cells do not suffer. After many years of work, we have created a universal system carrying much larger molecules than the world’s competition is currently doing. With our system, we can control the speed and depth of drug absorption so that it reaches only the affected tissues or the systemic circulation. This opens a new chapter for drug manufacturers – says Dr Paweł Biernat, President of Biotts in Wroclaw.

The team of Biotts technologists works at the Wroclaw Technology Park.